Cardiovascular benefits and improved patient survival by rosuvastatin treatment in hemodialyis patients are determined by normalization of CRP and LDL-cholesterol - A prospective analyis of the AURORA trial.

Bengt Fellström,Halvard Holdaas,Alan Jardine,Roland E. Schmieder,Mattis Gottlow,Jonsson Eva,Faiez Zannad

Cardiovascular benefits and improved patient survival by rosuvastatin treatment in hemodialyis patients are determined by normalization of CRP and LDL-cholesterol - A prospective analyis of the AURORA trial.

2011

Bengt Fellström
Halvard Holdaas
Alan Jardine
Roland E. Schmieder
Mattis Gottlow
Jonsson Eva
Faiez Zannad

Cardiovascular benefits and improved patient survival by rosuvastatin treatment in hemodialyis patients are determined by normalization of CRP and LDL-cholesterol - A prospective analyis of the AURORA trial.

Keywords:

Cholesterol
AURORA trial
Rosuvastatin
Normalization (statistics)
Physical therapy
Medicine
patient survival
Internal medicine
Intensive care medicine
ldl cholesterol

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations